Evidence map›Paper›PMID 39467647›Full record

ArticleGenome research2024

An optimized protocol for quality control of gene therapy vectors using nanopore direct RNA sequencing.

Kathleen Zeglinski, Christian Montellese, Matthew E Ritchie, Monther Alhamdoosh, Cédric Vonarburg, Rory Bowden, Monika Jordi, Quentin Gouil, Florian Aeschimann, Arthur Hsu

Abstract read
In one paragraph

Article in Genome research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Kathleen ZeglinskiWalter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, Victoria 3052, Australia; zeglinski.k@wehi.edu.au.ORCID 0000-0003-0608-229X
Christian MontelleseCSL Behring, Research, CH-3014 Bern, Switzerland.
Matthew E RitchieWalter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, Victoria 3052, Australia.ORCID 0000-0002-7383-0609
Monther AlhamdooshResearch Data Science Group, R&D, CSL, Parkville, Victoria 3000, Australia.ORCID 0000-0002-2411-1325
Cédric VonarburgCSL Behring, Research, CH-3014 Bern, Switzerland.
Rory BowdenWalter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, Victoria 3052, Australia.ORCID 0000-0001-8596-0366
Monika JordiCSL Behring, Research, CH-3014 Bern, Switzerland.
Quentin GouilWalter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, Victoria 3052, Australia.ORCID 0000-0002-5142-7886
Florian AeschimannCSL Behring, Research, CH-3014 Bern, Switzerland.ORCID 0000-0001-5213-034X
Arthur HsuResearch Data Science Group, R&D, CSL, Parkville, Victoria 3000, Australia.ORCID 0000-0001-8308-1106

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite recent advances made toward improving the efficacy of lentiviral gene therapies, a sizeable proportion of produced vector contains an incomplete and thus potentially nonfunctional RNA genome. This can undermine gene delivery by the lentivirus as well as increase manufacturing costs and must be improved to facilitate the widespread clinical implementation of lentiviral gene therapies. Here, we compare three long-read sequencing technologies for their ability to detect issues in vector design and determine nanopore direct RNA sequencing to be the most powerful. We show how this approach identifies and quantifies incomplete RNA caused by cryptic splicing and polyadenylation sites, including a potential cryptic polyadenylation site in the widely used Woodchuck Hepatitis Virus Posttranscriptional Regulatory Element (WPRE). Using artificial polyadenylation of the lentiviral RNA, we also identify multiple hairpin-associated truncations in the analyzed lentiviral vectors (LVs), which account for most of the detected RNA fragments. Finally, we show that these insights can be used for the optimization of LV design. In summary, nanopore direct RNA sequencing is a powerful tool for the quality control and optimization of LVs, which may help to improve lentivirus manufacturing and thus the development of higher quality lentiviral gene therapies.

Indexed as

Genetic TherapyGenetic VectorsLentivirusNanopore SequencingQuality ControlSequence Analysis, RNAHumansNanoporesPolyadenylationRNA, ViralRNA, Viral

Identifiers

PMID39467647
PMCPMC11610601

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.